Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0International Journal of Nanomedicine

Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy

6 affiliations
  1. 1Department of Respiratory Medicine, Luzhou Maternal & Child Health Hospital, Luzhou Second People’s Hospital, Luzhou Women and Children’s Hospital, Luzhou, Sichuan, 646000, People’s Republic of China
  2. 2Department of Health Management Center, Luzhou Maternal & Child Health Hospital, Luzhou Second People’s Hospital, Luzhou Women and Children’s Hospital, Luzhou, Sichuan, 646000, People’s Republic of China
  3. 3School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, 610500, People’s Republic of China
  4. 4Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, 310003, People’s Republic of China
  5. 5Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China
  6. 6Wolfson Institute for Biomedical Research, UCL Division of Medicine, University College London, London, WC1E 6BT, UK

Abstract

Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.

Related

  1. Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
    Yan Xu, Hui Guan, Yuan Wu +4
    Journal of translational internal medicinePeer-reviewedCC BYFull textOncologyEurope PMCEurope PMCPMC
  2. Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine
    Sabah Aafreen, Sayed Abdur Rehman, Tahmeed Parvez Barbhuiya +5
    NanomedicinePeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  3. A Narrative Review of Nanomedicine in Cancer Therapy: Modulating Metabolic Reprogramming to Enhance Immunotherapy.
    Hongpeng Wu, Fengyi Wang, Wei Sun +1
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
  4. Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy
    Jiayu Liu, Wenxia Shao, Qing Ye
    eBioMedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  5. Mechanism-Driven Nanomedicine for Radiation Injury and Protection: Redox Homeostasis, the DNA Damage Response, and Microbiome-Based Strategies.
    Han Li, Xinrui Du, Chengyuan Zhou +3
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMCPMC
BibTeX
@article{he2026nanomedicineenhanced,
  title = {{Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy}},
  author = {Xianye He and Jiao He and Zhongsong Zhang and Yuanyin Teng and Bing Wang and Hao Sun and Xiang Deng and Junjun Xiong and Yuzhuo Huang},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  month = nov,
  doi = {10.2147/ijn.s651751},
  url = {https://doi.org/10.2147/ijn.s651751},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
AU  - Xianye He
AU  - Jiao He
AU  - Zhongsong Zhang
AU  - Yuanyin Teng
AU  - Bing Wang
AU  - Hao Sun
AU  - Xiang Deng
AU  - Junjun Xiong
AU  - Yuzhuo Huang
PY  - 2026
DA  - 2026/11/08
JO  - International Journal of Nanomedicine
DO  - 10.2147/ijn.s651751
UR  - https://doi.org/10.2147/ijn.s651751
AB  - Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
SN  - 1176-9114
SN  - 1178-2013
ER  -